These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3083211)

  • 21. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes.
    Lowitt S; Malone JI; Salem AF; Korthals J; Benford S
    Metabolism; 1995 May; 44(5):677-80. PubMed ID: 7752919
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes.
    Malone JI; Lowitt S; Salem AF; Miranda C; Korthals JK; Carver J
    Metabolism; 1996 Jul; 45(7):902-7. PubMed ID: 8692029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of sorbinil treatment on red cell sorbitol levels and clinical and electrophysiological parameters of diabetic neuropathy.
    Lehtinen JM; Hyvönen SK; Uusitupa M; Puhakainen E; Halonen T; Kilpeläinen H
    J Neurol; 1986 Jun; 233(3):174-7. PubMed ID: 3522813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs.
    Engerman RL; Kern TS; Larson ME
    Diabetologia; 1994 Feb; 37(2):141-4. PubMed ID: 8163047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review of myo-inositol and sorbinil studies.
    Clements RS
    Clin Physiol; 1985; 5 Suppl 5():90-3. PubMed ID: 3938689
    [No Abstract]   [Full Text] [Related]  

  • 27. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase.
    Price SA; Agthong S; Middlemas AB; Tomlinson DR
    Diabetes; 2004 Jul; 53(7):1851-6. PubMed ID: 15220210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aldose reductase inhibitors and late complications of diabetes.
    Benfield P
    Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy.
    Young RJ; Ewing DJ; Clarke BF
    Diabetes; 1983 Oct; 32(10):938-42. PubMed ID: 6225686
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can aldose reductase inhibition ameliorate diabetic neuropathy?
    González ER
    JAMA; 1981 Sep; 246(11):1169-70. PubMed ID: 6790734
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study.
    Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N;
    Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor.
    Greene DA; Lattimer SA
    Am J Med; 1985 Nov; 79(5A):13-7. PubMed ID: 3000175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
    Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
    FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors.
    Jacobson M; Sharma YR; Cotlier E; Hollander JD
    Invest Ophthalmol Vis Sci; 1983 Oct; 24(10):1426-9. PubMed ID: 6413448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration: relationship to myo-inositol metabolism and nerve conduction slowing.
    Greene DA
    Metabolism; 1986 Apr; 35(4 Suppl 1):60-5. PubMed ID: 2421135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
    Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T;
    J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent clinical experience with aldose reductase inhibitors.
    Krans HM
    Diabet Med; 1993; 10 Suppl 2():44S-48S. PubMed ID: 8334842
    [No Abstract]   [Full Text] [Related]  

  • 39. Ranirestat for the management of diabetic sensorimotor polyneuropathy.
    Bril V; Hirose T; Tomioka S; Buchanan R;
    Diabetes Care; 2009 Jul; 32(7):1256-60. PubMed ID: 19366965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldose reductase inhibitors in clinical practice. Preliminary studies on diabetic neuropathy and retinopathy.
    Pitts NE; Gundersen K; Mehta DJ; Vreeland F; Shaw GL; Peterson MJ; Collier J
    Drugs; 1986; 32 Suppl 2():30-5. PubMed ID: 3098543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.